ReviewPharmacology & therapeutics2017
Anti-TNFα therapy in inflammatory lung diseases.
Review in Pharmacology & therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
130 citing papers in PubMed, 2 syntheses or guidelines pooled it, 234 citations in OpenAlex.
- Yinyanghuo () and its components for chronic obstructive pulmonary disease: preclinical evidence and possible mechanisms.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2023Pooled it
- Association between tumor necrosis factor alpha and obstructive sleep apnea in adults: a meta-analysis update.BMC pulmonary medicine · 2020Pooled it
- ROS scavenging mitigates TNFα-induced endoplasmic reticulum stress and mitochondrial fragmentation in human airway smooth muscle.Function (Oxford, England) · 2026Article
- Renal Tubular Epithelial Cells Senescence Induced by 1-Aminopyrene Activates Fibroblast via BRD4 Driven Senescence-Associated Secretory Phenotype Signaling.Journal of biochemical and molecular toxicology · 2026Article
- Regional and size-dependent effects of ambient agricultural particulate matter on Ah-receptor activity and inflammatory responses in human U937 macrophages.Inhalation toxicology · 2026Article
- Ultrasensitive detection of lung inflammation in male mice using immuno-magnetic particle imaging.Nature communications · 2026Article
- Inhibition of runt related transcription factor 1 with Ro24-7429 improves lung function in experimental models of idiopathic pulmonary fibrosis.Scientific reports · 2026Article
- Respiratory Biomarkers: An Opportunity for Patient-Centric Microsampling Approach for Treatment Optimization.Clinical and translational science · 2026Review
- Progressive Pulmonary Cystic Disease in Autoimmune Hepatitis and Rheumatoid Arthritis: A Rare Association.Cureus · 2026Article
- Alpha-defensins promote macrophage inflammatory activation via RNF31 signaling.Genes & genomics · 2026Article
- Lung Function Parameters during Anti-TNFα Therapy in Inflammatory Bowel Disease.The open respiratory medicine journal · 2026Article
- Article
- Positron Emission Tomography imaging of tumor necrosis factor in lung injury.Upsala journal of medical sciences · 2026Article
- The miR-146a/Human mutation · 2026Article
- Asthma in Patients With Confirmed Pulmonary Sarcoidosis.Canadian respiratory journal · 2026Review
- Case Report: TRNT1 related autoinflammatory syndrome in a patient with primary ciliary dyskinesia.Frontiers in immunology · 2026Article
- Clinical Characteristics and Early Risk Factors for SevereInfection and drug resistance · 2026Article
- Network pharmacology and in vitro studies demonstrate modulation of fibrotic pathways by Swertia chirayita in pulmonary fibrosis.Scientific reports · 2025Article
- RecombinantHuman vaccines & immunotherapeutics · 2025Article
- Modeling functional responses to pollutant exposure using modular hydrogel supported vascularized alveolosphere-on-a-chip.Biomaterials science · 2025Article
70 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Increased levels of tumor necrosis factor (TNF) α have been linked to a number of pulmonary inflammatory diseases including asthma, chronic obstructive pulmonary disease (COPD), acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), sarcoidosis, and interstitial pulmonary fibrosis (IPF). TNFα plays multiple roles in disease pathology by inducing an accumulation of inflammatory cells, stimulating the generation of inflammatory mediators, and causing oxidative and nitrosative stress, airway hyperresponsiveness and tissue remodeling. TNFα-targeting biologics, therefore, present a potentially highly efficacious treatment option. This review summarizes current knowledge on the role of TNFα in pulmonary disease pathologies, with a focus on the therapeutic potential of TNFα-targeting agents in treating inflammatory lung diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.